COVID-19 is forcing European laboratories to re-think where they test patients. Some are working with authorities to set up new ‘drive-through’ testing points, while others have closed more than half of their drawing points.
In the second of our two-part deep dive into how COVID-19 is hitting healthcare markets across EMEA, we ask how hospitals are coping with spiralling staff sickness and a flood of patients, and whether the care and dialysis sectors can stay afloat given the risk the virus poses to their most vulnerable patients.
Bupa, the global healthcare insurer and healthcare operator went from pre-tax profits of £502m in 2018 to a loss of £78m in 2019, thanks mainly to huge write-offs in its UK dentistry business and Australian care homes. But stripping out write-offs, underlying profitability still plunged 31%. Revenue rose just 4%. Why, and what does this tell us about Bupa and its future?
Occupational healthcare groups Medicover and Terveystalo are growing revenue at upwards of 25%, much faster than the 6-9% seen in other publicly listed groups so far this year. Historically employer-funded, individual pay is now growing three times faster than corporate. With Fresenius Helios setting out occupational healthcare expansion plans, what is the future of corporate pay?
MidEuropa has moved its Polish lab business to a second fund controlled by the private equity group with an eye to selling in four-five years, HBI understands.
HBI talks to Marcin Lukasiewicz, managing director for listed pan-CEE healthcare group Medicover's Polish hospital division, a c.€100m business. What are the prospects for the private Polish hospital market, considering the virulently anti-private sector PiS government was just re-elected for another four years?
The failure of Slovakian opposition parties to build a coalition or push through a bill banning verticalisation in healthcare could make a minority sale of Penta Investments's CEE hospital business PHI less likely.
Life Healthcare confirmed last week that it was looking to exit its Polish hospital business, Scanmed, citing further regulatory changes. Other investors are also looking to leave the country and assets that were expected to sell remain unsold. What went wrong in a market we once described as "stuff as dreams are made of"?
US-based asset management group Rohatyn Group (TRH) has invested in pan-European radiotherapy provider Amethyst, and will share control with the groups two founders.
Nearly a third of all private equity-owned health care businesses in Europe have been held for at least five years, according to the new HBI Deals Pipeline tool. That suggests many private equity houses are struggling to sell on their investments.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.